The U.S. Food and Drug Administration approved on Oct. 5 Boston Scientific’s Synergy bioabsorbable polymer drug-eluting stent, the first device of its kind to receive approval. The stent limits long-term polymer exposure by absorbing the abluminal bioabsorbable drug after three months when the drug elution is complete. According to the results of a study published Oct. 5 in the New England Journal of Medicine, reduced aortic-valve leaflet motion may occur in patients after transcatheter aortic-valve replacement or surgical abortive-valve replacement with a bioprosthetic valve, and “could be associated with subclinical leaflet thrombosis.” Read more on ACC.org.